Literature DB >> 25405162

Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.

Camilo Pena1, Leonardo Mirandola1, Jose A Figueroa1, Nattamol Hosiriluck1, Natallia Suvorava1, Kayley Trotter1, Adair Reidy1, Rahman Rakhshanda1, Drew Payne1, Marjorie Jenkins1, Fabio Grizzi1, Lauren Littlefield1, Maurizio Chiriva-Internati1, Everardo Cobos1.   

Abstract

Galectins are family of galactose-binding proteins known to play critical roles in inflammation and neoplastic progression. Galectins facilitate the growth and survival of neoplastic cells by regulating their cross-talk with the extracellular microenvironment and hampering anti-neoplastic immunity. Here, we review the role of galectins in the biology of hematological malignancies and their promise as potential therapeutic agents in these diseases.

Entities:  

Keywords:  Galectins; galectin-3 (Gal-3); leukemia; lymphomas; multiple myeloma (MM)

Year:  2014        PMID： 25405162      PMCID： PMC4205870          DOI： 10.3978/j.issn.2305-5839.2014.09.14

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  57 in total

Review 1.  Galectins, galactoside-binding mammalian lectins: clinical application of multi-functional proteins.

Authors:  J Wada; H Makino
Journal:  Acta Med Okayama       Date:  2001-02       Impact factor: 0.892

2.  Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1.

Authors:  D O Croci; P E Morande; S Dergan-Dylon; M Borge; M A Toscano; J C Stupirski; R F Bezares; J S Avalos; M Narbaitz; R Gamberale; G A Rabinovich; M Giordano
Journal:  Leukemia       Date:  2012-11-07       Impact factor: 11.528

3.  Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes.

Authors:  N L Perillo; C H Uittenbogaart; J T Nguyen; L G Baum
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

Review 4.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

5.  GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.

Authors:  Matthew J Streetly; Lenushka Maharaj; Simon Joel; Steve A Schey; John G Gribben; Finbarr E Cotter
Journal:  Blood       Date:  2010-02-26       Impact factor: 22.113

6.  Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection.

Authors:  Eva V Acosta-Rodríguez; Carolina L Montes; Claudia C Motrán; Elina I Zuniga; Fu-Tong Liu; Gabriel A Rabinovich; Adriana Gruppi
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

Review 7.  Recent progress and new perspectives in lymphoma glycobiology.

Authors:  Osamu Suzuki; Masafumi Abe
Journal:  Fukushima J Med Sci       Date:  2013

8.  Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow.

Authors:  Frédéric Mourcin; Caroline Breton; Julie Tellier; Priyanka Narang; Lionel Chasson; Audrey Jorquera; Mark Coles; Claudine Schiff; Stéphane J C Mancini
Journal:  Blood       Date:  2011-04-21       Impact factor: 22.113

9.  Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.

Authors:  Leonardo Mirandola; Yuefei Yu; Kitty Chui; Marjorie R Jenkins; Everardo Cobos; Constance M John; Maurizio Chiriva-Internati
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

10.  Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: regulatory roles of cell surface glycans.

Authors:  Osamu Suzuki; Masafumi Abe
Journal:  Int J Oncol       Date:  2014-03-04       Impact factor: 5.650
View more
  7 in total

1.  How to avoid being eaten: a lymphoma's defense.

Authors:  Nora Heisterkamp
Journal:  Blood       Date:  2016-04-14       Impact factor: 22.113

Review 2.  Galectin-9: From cell biology to complex disease dynamics.

Authors:  Sebastian John; Rashmi Mishra
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

Review 3.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

Review 4.  Extracellular galectins as controllers of cytokines in hematological cancer.

Authors:  Monica Gordon-Alonso; Annika M Bruger; Pierre van der Bruggen
Journal:  Blood       Date:  2018-06-06       Impact factor: 22.113

Review 5.  Role of Galectins in Multiple Myeloma.

Authors:  Paola Storti; Valentina Marchica; Nicola Giuliani
Journal:  Int J Mol Sci       Date:  2017-12-17       Impact factor: 5.923

Review 6.  Galectin-3, histone deacetylases, and Hedgehog signaling: Possible convergent targets in schistosomiasis-induced liver fibrosis.

Authors:  Felipe Leite de Oliveira; Katia Carneiro; José Marques Brito; Mariana Cabanel; Jonathas Xavier Pereira; Ligia de Almeida Paiva; Wingkin Syn; Neil C Henderson; Marcia Cury El-Cheikh
Journal:  PLoS Negl Trop Dis       Date:  2017-02-23

Review 7.  The emerging roles of exosomes in leukemogeneis.

Authors:  Jianbiao Zhou; Sam Wang; Kangyun Sun; Wee-Joo Chng
Journal:  Oncotarget       Date:  2016-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.